Seribantumab - Merrimack Pharmaceuticals

Drug Profile

Seribantumab - Merrimack Pharmaceuticals

Alternative Names: MM-121; SAR-256212

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merrimack Pharmaceuticals
  • Developer Merrimack Pharmaceuticals; Sanofi
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor modulators; ERBB-3 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Non-small cell lung cancer; Ovarian cancer
  • Phase I Gynaecological cancer; Solid tumours

Most Recent Events

  • 30 Oct 2017 Seribantumab receives Orphan Drug status for Non-small cell lung cancer in USA
  • 13 Sep 2017 Seribantumab is still in phase II trials for Non-small cell lung cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA (IV) (NCT02387216)
  • 31 Aug 2017 Merrimack Pharmaceuticals terminates a phase I trial due to internal decision in Solid tumours (Late-stage disease, Combination therapy) in USA (Parenteral) (NCT02538627)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top